+ Font size - | Print Print | Email to a Friend Email to a Friend |
Substitute Nav goes here.
Skip Navigation Links > Home > Gastric Cancer > Benefits of Taxotere®

Taxotere® Chemotherapy Benefits: Gastric Cancer

Taxotere® (docetaxel ) chemotherapy in combination with cisplatin and 5-fluorouracil (also called 5-FU) is the first FDA-approved treatment regimen in more than a decade to prolong the lives of people with gastric (stomach) cancer and cancer of the gastroesophageal (GE) junction.

Taxotere® offers many benefits to people living with gastric cancer. In a clinical trial (also called study) comparing the chemotherapy regimen of Taxotere® + cisplatin + 5-FU (TCF) to the historical standard regimen of cisplatin + 5-FU (CF) in the treatment of gastric cancer and cancer of the gastroesophageal (GE) junction, people receiving TCF experienced advantages like the following:

  • Improved survival 9.2(TCF) vs 8.6(CF) months
  • Tumor shrinkage
  • Lower risk of disease progression in patients receiving (TCF) 5.6 vs (CF) 3.7 months

More Details Of Taxotere® Chemotherapy For Gastric

Taxotere® Chemotherapy Proven Effective in Gastric Cancer Study

Taxotere® plus cisplatin and 5-FU received approval from the Food and Drug Administration (FDA ) for the first-line treatment of advanced gastric adenocarcinoma (including the area where the stomach and esophagus connect).

This FDA approval was based on a study that proved the effectiveness of Taxotere® + cisplatin + 5-FU (TCF) compared to the chemotherapy regimen of cisplatin + 5-FU (CF).

The Taxotere®-based regimen, TCF, demonstrated the following advantages over CF:

  • Improved survival: Many people receiving TCF lived longer 9.2(TCF) vs 8.6(CF) months.
  • 22% reduced chance of death from the cancer.
  • Tumor shrinkage 11.3% more people responded to TCF compared to CF.
  • Lower risk of disease progression: More people receiving TCF had a lower risk of their cancer progressing. For those who did experience cancer progression, the progression was delayed longer than progression in people receiving CF.
  • Greater ability to tolerate chemotherapy treatment: More people receiving TCF stayed on treatment longer.

For more information, visit the Taxotere® Side Effects page in this section.

Helpful Resources

Chemotherapy can be managed through education preparation. To be better equipped to help yourself and your family, visit the Helpful Resource section.

learn more
Helpful Resources
Prescribing Information | Site Map | Terms of Use | Privacy Policy | Contact Us
© 2002- 2008 sanofi-aventis U.S. LLC. All rights reserved.
Legal Disclaimer Information and Privacy Policy
Questions or Comments? Click here to contact us.
This site intended for use by U.S. residents only.
US.DOC.08.02.059  Last update:  April 2008
Important Safety Information

WARNING: Taxotere® treatment can cause serious, physically limiting, and potentially life-threatening side effects, such as infection, low blood-cell counts, allergic reaction, and retention of excess fluid (edema).

Taxotere® should not be given to patients with low white–blood-cell counts, abnormal liver function, or a history of allergic reactions to Taxotere® or any of the ingredients in Taxotere®.

Before each Taxotere® treatment, all patients treated with Taxotere® must receive another medicine called dexamethasone. This drug can help reduce the risk of fluid retention (edema) and allergic reactions.

Taxotere® should be administered only under the supervision of a qualified physician experienced in the use of anticancer treatments. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

Treatment-related acute myeloid leukemia (AML) or myelodysplasia has occurred in patients given anthracyclines and/or cyclophosphamide, including use with Taxotere® in adjuvant therapy for breast cancer.

The most common severe side effects are low white–blood-cell count, anemia, fatigue, diarrhea, and mouth and throat irritation. Low white–blood-cell count can lead to life-threatening infections. The earliest sign of infection may be fever, so tell your doctor right away if you have a fever.

Other common side effects from Taxotere® include nausea, vomiting, hair loss, rash, infusion-site reactions, odd sensations (such as numbness, tingling, or burning) or weakness in the hands and feet, nail changes, muscle and/or bone pain, or excessive tearing.

Because of the potential risk of fetal harm, pregnant women should not receive Taxotere®. Women of childbearing potential should avoid becoming pregnant during treatment with Taxotere®.

Before receiving Taxotere®, tell your doctor if

  • You have any allergies
  • You are taking any other medicines — including nonprescription (over-the-counter) drugs, vitamins, and dietary or herbal supplements

When taking Taxotere®, contact your doctor if

  • You have symptoms of an allergic reaction (warm sensation, tightness in your chest, itching/hives, or shortness of breath)
  • You experience any other side effects

Please see adjacent page for patient information leaflet for detailed information about these side effects, and talk to your doctor about any questions you may have.

Taxotere Indications

Breast Cancer
TAXOTERE® is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy
TAXOTERE® in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer

Non-Small Cell Lung Cancer
TAXOTERE®, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy
TAXOTERE® in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic NSCLC who have not previously received chemotherapy for this condition.

Prostate Cancer
TAXOTERE® in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

Gastric Cancer
TAXOTERE® in combination with cisplatin and flouroucil is indicated for the treatment of patients with advanced gastric adenocercinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.

Head and neck Cancer
TAXOTERE® in combination with cisplatin and flourouracil is indicated for the induction treatment of patients with locally advanced squamous cell cercinoma of the head and neck (SCCHN).